{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:05:42Z","timestamp":1778252742753,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40121-019-00267-4","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T12:03:53Z","timestamp":1570622633000},"page":"641-655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Use of Antifungals and Outcomes Among Inpatients at Risk of Invasive Aspergillosis or Mucormycosis in the USA: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"8","author":[{"given":"Katherine","family":"Stull","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Esterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayank","family":"Ajmera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Candrilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Therese M.","family":"Kitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Spalding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa Perez","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"issue":"2","key":"267_CR1","first-page":"195","volume":"139","author":"P Badiee","year":"2014","unstructured":"Badiee P, Hashemizadeh Z. Opportunistic invasive fungal infections: diagnosis & clinical management. Indian J Med Res. 2014;139(2):195\u2013204.","journal-title":"Indian J Med Res"},{"key":"267_CR2","first-page":"79","volume":"9","author":"MA Donnelley","year":"2016","unstructured":"Donnelley MA, Zhu ES, Thompson GR III. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infect Drug Resist. 2016;9:79\u201386.","journal-title":"Infect Drug Resist."},{"issue":"6","key":"267_CR3","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1378\/chest.121.6.1988","volume":"121","author":"AO Soubani","year":"2002","unstructured":"Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest. 2002;121(6):1988\u201399.","journal-title":"Chest"},{"key":"267_CR4","doi-asserted-by":"crossref","unstructured":"Gavald\u00e0 J, Meije Y, Fort\u00fan J et al, ESCMID Study Group for Infections in Compromised Hosts. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):27\u201348.","DOI":"10.1111\/1469-0691.12660"},{"issue":"2","key":"267_CR5","doi-asserted-by":"publisher","first-page":"J77","DOI":"10.3314\/mmj.57.J77","volume":"57","author":"S Kimura","year":"2016","unstructured":"Kimura S. Invasive aspergillosis in hematological patients. Med Mycol J. 2016;57(2):J77\u201388.","journal-title":"Med Mycol J."},{"issue":"7","key":"267_CR6","first-page":"986","volume":"91","author":"G Chamilos","year":"2006","unstructured":"Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989\u20132003). Haematologica. 2006;91(7):986\u20139.","journal-title":"Haematologica"},{"issue":"1","key":"267_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12879-016-2023-z","volume":"16","author":"DP Kontoyiannis","year":"2016","unstructured":"Kontoyiannis DP, Yang H, Song J, et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis. 2016;16(1):730.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"267_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3324\/haematol.2009.012054","volume":"95","author":"L Pagano","year":"2010","unstructured":"Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. Haematologica. 2010;95(4):644\u201350.","journal-title":"Haematologica"},{"issue":"8","key":"267_CR9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1086\/651262","volume":"50","author":"PG Pappas","year":"2010","unstructured":"Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101\u201311.","journal-title":"Clin Infect Dis"},{"key":"267_CR10","doi-asserted-by":"crossref","unstructured":"Vallabhaneni S, Benedict K, Derado G, Mody RK. Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000\u20132013. Open Forum Infect Dis. 2017;4(1):ofw268.","DOI":"10.1093\/ofid\/ofw268"},{"issue":"10020","key":"267_CR11","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760\u20139.","journal-title":"Lancet"},{"issue":"6","key":"267_CR12","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408\u201315.","journal-title":"N Engl J Med"},{"issue":"1","key":"267_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1086\/508774","volume":"44","author":"TJ Walsh","year":"2007","unstructured":"Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2\u201312.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"267_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.diagmicrobio.2012.06.012","volume":"73","author":"N Azie","year":"2012","unstructured":"Azie N, Neofytos D, Pfaller M, Meier-Kriesche H-U, Quan S-P, Horn D. The PATH (prospective antifungal therapy) Alliance\u00ae registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73(4):293\u2013300.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"267_CR15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/myc.12023","volume":"56","author":"WJ Heinz","year":"2013","unstructured":"Heinz WJ, Egerer G, Lellek H, Boehme A, Greiner J. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses. 2013;56(3):304\u201310.","journal-title":"Mycoses"},{"issue":"12","key":"267_CR16","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1592\/phco.27.12.1644","volume":"27","author":"LS Chou","year":"2007","unstructured":"Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy. 2007;27(12):1644\u201350.","journal-title":"Pharmacotherapy"},{"key":"267_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/cam4.225","volume":"3","author":"H Kung","year":"2014","unstructured":"Kung H, Johnson MD, Drew RH, Saha-Chaudhuri P, Perfect JR. Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology\u2013oncology patients: a retrospective cohort study. Cancer Med. 2014;3:667\u201373.","journal-title":"Cancer Med"},{"issue":"4","key":"267_CR18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR III, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1\u201360.","journal-title":"Clin Infect Dis"},{"key":"267_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3352\/jeehp.2013.10.12","volume":"10","author":"V Matt","year":"2013","unstructured":"Matt V, Matthew H. The retrospective chart review: important methodological considerations. J Educ Eval Health Prof. 2013;10:12.","journal-title":"J Educ Eval Health Prof."},{"issue":"12","key":"267_CR20","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"267_CR21","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1086\/313498","volume":"29","author":"JR Wingard","year":"1999","unstructured":"Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999;29(6):1402\u20137.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"267_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/1471-2334-14-310","volume":"14","author":"MD Zilberberg","year":"2014","unstructured":"Zilberberg MD, Shorr AF, Huang H, Chaudhari P, Paly VF, Menzin J. Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data. BMC Infect Dis. 2014;14(1):310.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"267_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13054-014-0722-7","volume":"19","author":"FS Taccone","year":"2015","unstructured":"Taccone FS, Van den Abeele A-M, Bulpa P, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19(1):7.","journal-title":"Crit Care"},{"key":"267_CR24","doi-asserted-by":"crossref","unstructured":"Lortholary O, Gangneux J, Sitbon K, et al., French Mycosis Study Group. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005\u20132007). Clin Microbiol Infect. 2011;17(12):1882\u20139.","DOI":"10.1111\/j.1469-0691.2011.03548.x"},{"key":"267_CR25","first-page":"13","volume":"23","author":"JW Baddley","year":"2013","unstructured":"Baddley JW, Ephens JM, Ji X, Gao X, Schlamm HT, Tarallo M. Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes. BMC Infect Dis. 2013;23:13\u201329.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"267_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/myc.12727","volume":"61","author":"M Hoenigl","year":"2018","unstructured":"Hoenigl M, Prattes J, Neumeister P, W\u00f6lfler A, Krause R. Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: an illustrative case study. Mycoses. 2018;61(3):201\u20135.","journal-title":"Mycoses"},{"issue":"1","key":"267_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cpdd.284","volume":"6","author":"AH Groll","year":"2017","unstructured":"Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):76\u201385.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"10","key":"267_CR28","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1086\/497126","volume":"41","author":"TF Patterson","year":"2005","unstructured":"Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis. 2005;41(10):1448\u201352.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"267_CR29","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s10096-011-1425-5","volume":"31","author":"F Jacobs","year":"2012","unstructured":"Jacobs F, Selleslag D, Aoun M, Sonet A, Gadisseur A. An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole. Eur J Clin Microbiol Infect Dis. 2012;31(6):1173\u20139.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"267_CR30","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1111\/j.1439-0507.2010.01903.x","volume":"54","author":"A Kim","year":"2011","unstructured":"Kim A, Nicolau DP, Kuti JL. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses. 2011;54(5):e301\u201312.","journal-title":"Mycoses"},{"issue":"12","key":"267_CR31","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1086\/591531","volume":"47","author":"L Slobbe","year":"2008","unstructured":"Slobbe L, Polinder S, Doorduijn JK, et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia\u2013myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis. 2008;47(12):1507\u201312.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"267_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.otohns.2010.05.007","volume":"143","author":"JT Rich","year":"2010","unstructured":"Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan\u2013Meier curves. Otolaryngol Head Neck Surg. 2010;143(3):331\u20136.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"267_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","volume":"162","author":"KA Marr","year":"2015","unstructured":"Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81\u20139.","journal-title":"Ann Intern Med"},{"issue":"5","key":"267_CR34","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.ijantimicag.2018.08.005","volume":"52","author":"JD Jenks","year":"2018","unstructured":"Jenks JD, Reed SL, Seidel D, et al. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents. 2018;52(5):706\u201312.","journal-title":"Int J Antimicrob Agents"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-019-00267-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-019-00267-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-019-00267-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T06:26:40Z","timestamp":1715668000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-019-00267-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["267"],"URL":"https:\/\/doi.org\/10.1007\/s40121-019-00267-4","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,9]]},"assertion":[{"value":"22 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}